Physician profile
William David Boothe
NPI 1205832425
$1,680.26
in general payments reported to CMS, 2019-2025
19 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $414 · 2020: $275 · 2021: $339 · 2022: $168 · 2023: $153 · 2024: $58.37 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $222.09 | 2020 | |
| Sun Pharmaceutical Industries INC. | $221.49 | 2019-2023 | Cequa |
| Abbvie INC. | $196.35 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Aerie Pharmaceuticals, INC. | $158.69 | 2019-2021 | |
| Optos, INC. | $157.71 | 2021 | |
| Alcon Vision LLC | $145.60 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $139.07 | 2019-2021 | |
| Ocular Therapeutix, INC. | $78.86 | 2023-2025 | Dextenza |
| Celgene Corporation | $68.26 | 2019 | |
| Astellas Pharma US INC | $64.81 | 2025 | Izervay |
| Alimera Sciences, INC. | $41.13 | 2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $34.23 | 2025 | Eylea Hd |
| Foundation Medicine, INC. | $32.56 | 2019 | |
| Mallinckrodt Hospital Products INC. | $28.01 | 2025 | Acthar |
| Vyne Pharmaceuticals INC. | $25.04 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $18.34 | 2021 | |
| Amgen INC. | $17.71 | 2025 | Tepezza |
| Allergan, INC. | $16.50 | 2019 | |
| Janssen Biotech, INC. | $13.81 | 2025 | Tremfya, Simponi, Stelara |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Boothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.